OPTN (Option Therapeutics) Research & Development: $0.16 Mil (TTM As of Dec. 2025)


What is Option Therapeutics Research & Development?

Option Therapeutics OPTN Research & Development is $0.16 Mil as of Dec. 2025.

Research & Development is the aggregate amount of research and development expenses during the year. Option Therapeutics's Research & Development for the three months ended in Dec. 2025 was $0.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.16 Mil.

Option Therapeutics  (AMEX:OPTN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Option Therapeutics Research & Development Related Terms

Option Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Research & Development Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Research & Development
1.16 0.49

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial 0.01 0.10 0.00 0.09 0.07

Option Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.16 Mil mean?
Option Therapeutics (OPTN) has a Research & Development of $0.16 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' Research & Development too high?
Option Therapeutics' current Research & Development is $0.16 Mil.
How does Option Therapeutics' Research & Development compare to ?
Option Therapeutics' Research & Development of $0.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Option Therapeutics and its competitors. Option Therapeutics's current Research & Development is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Research & Development of $0.16 Mil. The current Research & Development is $0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Research & Development is $0.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.